Jefferies Assumes, Upgrades Protalix BioTherapeutics (PLX) at Buy (Earlier)
Tweet Send to a Friend
Jefferies assumed and upgraded Protalix BioTherapeutics (NYSE: PLX) with a Buy rating and a price target of $2.60 (from $2.00).Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
